Coformycin

DBCAT000965Pharmacologic class

A ribonucleoside antibiotic synergist and adenosine deaminase inhibitor isolated from Nocardia interforma and Streptomyces kaniharaensis. It is proposed as an antineoplastic synergist and immunosuppressant. A DrugBank category of 1 drug. 1 of them is approved.

Drugs: Pentostatin

What you can answer from here — as of August 24, 2016

1DrugEach linked to its full drug card

Listed above

1Drug targetEvery drug–target pair in the class, with bond type

7Marketed productsAcross the regions we cover, with dosage forms and routes

2Routes of administrationHow the drugs in this class are given

Which targets do Coformycin share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account